Epoch Biodesign key facts
as of Oct 2026- Operator of industrial biotechnology services intended to address the environmental and economic challenges posed by plastic waste.
- Epoch Biodesign is valued at approximately $52.4M as of Oct 2026 (last reported valuation).
- It has raised $64.1M; the latest was Later Stage VC ($12.0M) in Mar 2026.
- Notable investors include Plug and Play Tech Center, Innovate UK, BoxGroup, Tech Nation Group, Lowercarbon Capital — 30 tracked in total.
- Status: Privately Held (backing).
Epoch Biodesign's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·The complete investor list: 30 names
- ·Watch Epoch Biodesign: the Monday email on marks, rounds and moves
Epoch Biodesign funding rounds
No funding rounds for Epoch Biodesign are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Epoch Biodesign
30+Epoch Biodesign valuation
Epoch Biodesign's last reported valuation was $52.4 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
Epoch Biodesign investors
30 investors are on record for Epoch Biodesign, including Plug and Play Tech Center, Innovate UK, BoxGroup and Tech Nation Group. By type, the record holds 9 venture capital firms and 2 family offices.
About Epoch Biodesign
Operator of industrial biotechnology services intended to address the environmental and economic challenges posed by plastic waste. The company designs and develops enzymes by combining biology, artificial intelligence, and engineering capable of breaking down plastics into reusable chemicals, enabling industries to reduce plastic waste and enhance sustainability.
- Sector
- Business Products and Services (B2B)
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 56
- Website
- epochbiodesign.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.